A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-l-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder

International Journal of Neuropsychopharmacology

Volumn 5, Issue 4, 2002, Pages 287-294

  Pancheri, Paolo ^a,b   Scapicchio, Pierluigi ^c   Delle Chiaie, Roberto ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Fondazione Italiana per lo Studio Della Schizofrenia   (Italy)

^c Societa Italiana di Psichiatria   (Italy)

Author keywords

Imipramine; Major depression; S adenosyl L methionine

Indexed keywords

IMIPRAMINE; S ADENOSYLMETHIONINE; S ADENOSYLMETHIONINE 1,4 BUTANE DISULFONATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HAMILTON SCALE; HEART BEAT; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; P WAVE; PARALLEL DESIGN; PRIORITY JOURNAL; Q WAVE; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; ST SEGMENT; SUICIDE ATTEMPT; TACHYCARDIA; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIPRAMINE; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; S-ADENOSYLMETHIONINE;

EID: 0036903944     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145702003085     Document Type: Article

References (35)

1. Anderson IM (1998). SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depression and Anxiety 7 (Suppl. 1), 11-17.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th Edn). Washington, DC: American Psychiatric Association.
3. Baldessarini RJ (1975). Biological transmethylation involving S-adenosylmethionine: Development of assay methods and implications for neuropsychiatry. International Review of Neurobiology 18, 41-67.
4. Barberi A, Pusateri P (1978). The clinical effects of S-adenosyl-L-methionine (SAMe) in depressive disorders [in Italian]. Minerva Medica 19, 235-243.
5. Bell KM, Plon L, Bunney WE, Potkin SG (1988). SAMe treatment of depression: A controlled clinical trial. American Journal of Psychiatry 145, 1110-1114.
6. Bell KM, Potkin SG, Carreon D, Plon L (1994). S-adenosyl-methionine blood levels in major depression: Changes with drug treatment. Acta Neurologica Scandinavica 154, 15-18.
7. Benelli A, Filaferro M, Bertolini A, Genedani S (1999). Influence of S-adenosyl-L-methionine on chronic mild stress-induced anhedonia in castred rats. British Journal of Pharmacology 127, 645-654.
8. Bottiglieri T, Godfrey P, Flynn T, Carney MWP, Toone BK, Reynolds EH (1990). Cerebrospinal fluid S-adenosylmethionine in depression and dementia: Effect of treatment with parenteral and oral S-adenosylmethionine. Journal of Neurology, Neurosurgery, and Psychiatry 53, 1096-1098.
9. Bressa GM (1994). S-adenosyl-L-methionine (SAMe) as antidepressant: Meta-analysis of clinical studies. Acta Neurologica Scandinavica 89 (Suppl. 154), 7-14.
10. Campbell LK, Robison LM, Skaer TL (1997). Depression: Interventions and their effectiveness. Disease Management and Health Outcomes 2, 223-237.
11. Cantoni GL (1953). S-adenosylmethionine; a new intermediate formed enzymatically from L-methionine and adenosine triphosphate. Journal Biological Chemistry 204, 403-416.
12. Caruso I, Fumagalli M, Boccassini L (1987). Treatment of depression in rheumatoid arthritic patients. A comparison of S-adenosylmethionine (Samyr) and placebo in a double-blind study. Clinical Trials 24, 305-310.
13. Cimino M, Vantini G, Algeri S (1984). Age modification of dopaminergic and beta-adrenergic receptor systems: Restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Science 34, 2029-2039.
14. Consogno E, Tiraboschi E, Juliano E, Gennarelli M, Racagni G, Popoli M (2001). Long-term treatment with S-adenosylmethionine induced changes in presynaptic CaM kinase II and synapsin I. Biological Psychiatry 50, 337-344.
15. Curcio M, Catto E, Stramentinoli G, Algeri S (1978). Effect of S-adenosylmethionine on serotonin metabolism in rat brain. Progress in Neuro-Psychopharmacology 2, 65-71.
16. Danish University Antidepressant Group (DUAG) (1986). Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 90, 131-138.
17. Danish University Antidepressant Group (DUAG) (1990). Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 18, 289-299.
18. Danish University Antidepressant Group (DUAG) (1993). Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 28, 105-116.
19. Del Vecchio M, Iorio G, Cocorullo M, Vacca I, Amati A (1978). Has SAMe an antidepressant effect? A preliminary trial vs. clomipramine. Rivista Sperimentale di Freniatria 102, 344-358.
20. De Vanna M, Rigamonti R (1992). Oral S-adenosylmethionine in depression. Current Therapeutic Research 52, 478-485.
21. Fazio C, Andreoli V, Agnoli A, Casacchia M, Cerbo R (1973). Therapeutic effects and mechanism of action of S- adenosylmethionine (SAMe) in depressive disorders [in Italian]. Minerva Medica 64, 1515-1529.
22. Garattini S, Bertele V (2001). Adjusting Europe's drug regulation to public health needs. Lancet 358, 64-67.
23. Genedani S, Saltini S, Benelli A, Filaferro M, Bertolini A (2001). Influence of SAMe on the modifications of brain polyamine levels in an animal model of depression. NeuroReport 12, 1-4.
24. Kagan BL, Sultzer DL, Rosenlicht N, Gemer RH (1990). Oral S-adenosylmethionine in depression: A randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry 147, 191-195.
25. Kufferle B, Grunberger J (1982). Early clinical double blind study with SAMe: A new potential antidepressant. In: Costa E, Racagni G (Eds.), Typical and Atypical Antidepressants: Clinical Practice. New York: Raven Press.
26. Miccoli L, Porro V, Bertolino A (1978). Comparison between the antidepressant activity of S-adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurologica 33, 243-255.
27. Muccioli G, Scordamaglia A, Bertacco S, Di Carlo R (1992). Effect of S-adenosylmethionine on brain muscarinic receptors of aged rats. European Journal of Pharmacology 227, 293-299.
28. Muscettola G, Galzenati M, Balbi A (1982). SAMe versus placebo: A double blind comparison in major depressive disorder. In: Costa E, Racagni G (Eds.), Typical and Atypical Antidepressants: Clinical Practice (pp. 151-156). New York: Raven Press.
29. Otero-Losada ME, Rubio MC (1989a). Acute changes in 5-HT metabolism after S-adenosylmethionine administration. General Pharmacology 20, 403-406.
30. Otero-Losada ME, Rubio MC (1989b). Acute effects of S-adenosylmethionine on catecholaminergic central function. European Journal of Pharmacology 163, 353-356.
31. Pancheri P, Racagni G, Delle Chiaie R, Popoli M (1997). New experimental and clinical acquisitions on the efficacy and tolerability of SAMe as an antidepressant [in Italian]. Giornale Italiano di Psicopatologia 2, 1-23.
32. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C (1993). Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychotherapy and Psychosomatics 59, 34-40.
33. Scaggion G, Baldan L, Domanin S (1982). Antidepressant activity of SAMe compared with nomifensine maleate. Minerva Psichiatrica 23, 93-97.
34. Spillmann M, Fava M (1996). S-adenosylmethionine (SAMe) in psychiatric disorders. Historical perspective and current status. CNS Drugs 6, 416-428.
35. Zanotti S, Mori S, Radaelli R, Perez J, Racagni G, Popoli M (1998). Modification in brain cAMP- and calcium/calmodulin-dependent protein kinases induced by treatment with S-adenosylmethionine. Neuropharmacology 37, 1081-1089.